Notes to the consolidated statements of income

Schedule of disaggregation of revenue by categories

Disaggregation of revenue by categories

in € K


	For the three months ended		For the six months ended
	June 30,		June 30,
	2026	2025	2026	2025
Care Delivery	3,478,314	3,380,682	6,771,882	6,827,510
Thereof: U.S.	2,896,823	2,817,322	5,662,243	5,708,592
Thereof: International	581,491	563,360	1,109,639	1,118,918
Value-Based Care	536,137	505,695	1,026,507	1,035,186
Care Enablement	1,371,060	1,347,843	2,670,053	2,714,775
Inter-segment eliminations	(524,945)	(442,507)	(995,729)	(904,304)
Total	4,860,566	4,791,713	9,472,713	9,673,167

Schedule of amounts included in other operating income

Other operating income

in € K


		For the three months ended				For the six months ended
		June 30,				June 30,
		2026		2025		2026		2025
Foreign exchange gains		169,696		293,395		294,442		408,311
Gains on right-of-use assets, from the sale of fixed assets, clinics and investments		(1,682)		4,109		13,693		6,571
Revaluation of certain investments ⁽¹⁾		3,258		7,506		3,258		7,506
Income from strategic transactions and programs		14,264		7,483		14,264		7,937
Changes in fair value of the derivatives embedded in Virtual Power Purchase Agreements (vPPAs)		100		18,810		4,111		28,597
Other		21,970		11,642		36,223		25,338
Other operating income		207,606		342,945		365,991		484,260

Schedule of expenses from strategic transactions and programs

Expenses from strategic transactions and programs

in € K


		For the three months ended			For the six months ended
		June 30,			June 30,
		2026		2025	2026		2025
Impairment of intangible and tangible assets⁽¹⁾		18,559		10,861	123,695		12,468
Legacy Portfolio Optimization		227		10,540	227		12,147
FME25+ Program		18,332		321	123,468		321
Impairment resulting from the measurement of assets held for sale		—		2,846	—		8,864
Legacy Portfolio Optimization		—		2,846	—		8,864
Loss from the sale of business		—		—	650		—
Legacy Portfolio Optimization		—		—	650		—
Other⁽²⁾		12,045		2,269	41,247		19,527
FME25+ Program		3,369		—	21,781		—
Legacy Portfolio Optimization		8,676		1,116	19,466		18,065
Legal Form Conversion Costs		—		1,153	—		1,462
Expenses from strategic transactions and programs		30,604		15,976	165,592		40,859

(1)	For the three and six months ended June 30, 2026 and 2025, the amounts primarily relate to costs of revenue and, to a lesser extent, to selling, general and administrative expense.

(2)

For the three months ended June 30, 2026, the amounts relate primarily to selling, general and administrative expense and, to a lesser extent, to costs of revenue. For the six months ended June 30, 2026, the amounts primarily relate to costs of revenue and, to a lesser extent, to selling, general and administrative expense. For the three and six months ended June 30, 2025, the amounts primarily relate to selling, general and administrative expense.

Schedule of number of shares acquired in the context of the share buyback programs

Treasury Stock


						Total number of
						shares purchased		Maximum value of
						and retired		shares that may yet
						as part of publicly		be purchased under
		Total number of		Average price per		announced plans or		the plans or
Period		shares purchased		share		programs		programs
				in €				in € K

August 2025		2,084,733		42.68		2,084,733		511,021
September 2025		1,479,790		42.45		1,479,790		448,210
October 2025		788,260		46.38		788,260		411,651
November 2025		4,164,232		41.10		4,164,232		240,485
December 2025		5,607,549		40.26		5,607,549		—
January 2026		2,898,373		37.29		2,898,373		305,474
February 2026		2,596,794		39.67		2,596,794		202,449
March 2026		3,705,233		38.72		3,705,233		58,973
April 2026		1,523,855		38.67		1,523,855		—
May 2026		155,000		37.15		155,000		594,242
June 2026		2,299,945		39.49		2,299,945		503,409
Total repurchased shares ⁽¹⁾		27,303,764		40.12		27,303,764		503,409

Cancellation of repurchased shares		24,848,819		40.19		24,848,819		—

Treasury Stock held on June 30, 2026		2,454,945		39.35		2,454,945		—

(1)

The difference between the maximum value of shares that may yet be purchased under the Company’s share buyback program and the liability for such shares of €19,281 as of June 30, 2026 results from the timing of payments made for share repurchases on a weekly basis. The difference is recorded in the consolidated statements of equity within Additional paid-in capital.